Source comparison
Hexarelin vs MK-677: Research Application Comparison
Peak GH Output 40–60 ng/mL within 20–30 min (8–12× baseline) 10–20 ng/mL sustained (2–4× baseline) Hexarelin wins for acute GH studies; MK-677 for cumulative exposure Tolerance Development 60–70% attenuation by day 21 (receptor downregulation) No significant t
This comparison does not assign a generated winner or score.
- Peak GH Output
- 40–60 ng/mL within 20–30 min (8–12× baseline)
- 10–20 ng/mL sustained (2–4× baseline)
- Hexarelin wins for acute GH studies; MK-677 for cumulative exposure
- Tolerance Development
- 60–70% attenuation by day 21 (receptor downregulation)
- No significant tolerance through 6+ months
- MK-677 is the only option for protocols beyond 4 weeks
- IGF-1 Elevation
- Modest (15–25% increase, short duration)
- Sustained 60–80% increase from baseline
- MK-677 produces clinically meaningful IGF-1 changes
- Administration
- Subcutaneous injection, twice daily optimal
- Oral capsule, once daily
- MK-677 eliminates injection compliance issues
- Half-Life
- 70 minutes (requires frequent dosing)
- 4–6 hours (plus active metabolites extend effect to 24h)
- MK-677's pharmacokinetics support once-daily dosing
- Receptor Mechanism
- High-affinity GHS-R1a agonist (triggers internalisation)
- Moderate-affinity agonist (avoids β-arrestin recruitment)
- Mechanistic difference explains tolerance divergence
- Ideal Research Context
- Short-term GH pulse studies, acute metabolic response
- Chronic GH elevation, body composition, bone density, sleep
- Select based on study duration and peak vs AUC priority